Introduction
============

Systemic lupus erythematosus (SLE) is a heterogeneous chronic systemic autoimmune disease, which mainly affects women (90%). As treatment for lupus itself has gradually improved, mortality rates have declined and cardiovascular co-morbidity has become a growing clinical problem. Circulatory diseases are today a leading cause of mortality among SLE patients \[[@B1],[@B2]\].

Traditional coronary artery disease (CAD) risk factors are more prevalent among SLE patients than in the general population \[[@B3],[@B4]\] but they do not alone account for the high incidence of premature cardiovascular disease (CVD) seen in SLE \[[@B5],[@B6]\]. Additionally, several SLE associated risk factors have been identified such as pro-thrombotic antiphospholipid antibodies (aPL) \[[@B4],[@B7],[@B8]\], accelerated endothelial cell apoptosis and impaired repair of damaged endothelium \[[@B9],[@B10]\], oxidized low density lipoprotein (LDL) \[[@B11]\], pro-inflammatory high density lipoprotein (HDL) \[[@B12]\], genetic susceptibility \[[@B13]\] and decreased endothelial binding of annexin V \[[@B14]\]. The role of these and other mechanisms for premature cardiovascular morbidity and mortality seen in SLE are presently under intense study by many research groups.

Prospective studies that evaluate both traditional and lupus associated risk factors for hard endpoints, that is, CVEs, are to date relatively few in SLE \[[@B8],[@B15],[@B16]\] and outnumbered by studies focused on subclinical atherosclerosis in these patients \[[@B4],[@B17],[@B18]\]. But, measurements of atherosclerosis are surrogate markers of CVD and given the complexity of SLE, accelerated atherosclerosis may not be the only biologically plausible connection to CVEs. Other factors in an immunologically active setting like SLE may influence the likelihood of CVEs. It is therefore important to perform longitudinal studies in well-characterized SLE patients and to use hard endpoints such as myocardial infarction and stroke.

In a single center cohort of SLE patients, we selected patients free from clinical CVD and investigated the impact of traditional CAD risk factors, lupus associated biomarkers and clinical manifestations/features on the risk of presenting with a first ever CVE during eight years of follow-up.

Materials and methods
=====================

Patients
--------

All SLE patients at the Department of Rheumatology, Karolinska University Hospital who fulfilled four or more of the 1982 revised American College of Rheumatology Criteria for classification of SLE \[[@B19]\] during the inclusion period (1995-99) were asked to participate. A total of 182 of 208 (87.5%) participants were free of previous CVEs and were included in this study. 94% of the patients were European Caucasians and six percent were of Asian origin.

At follow-up (2004-2007) living patients were reinvestigated in person when possible. If not, they were interviewed by telephone. Medical charts were reviewed for all patients and death certificates were collected from all deceased patients. Autopsy protocols were collected when available. The Local Ethics Committee of the Karolinska University Hospital approved the study. All patients gave informed consent to participate.

Data collection
---------------

At baseline, patients were interviewed and examined by a rheumatologist who evaluated disease activity using Systemic Lupus Activity Measure (SLAM) \[[@B20]\] and organ damage with Systemic Lupus International Collaborating Clinics damage index (SLICC) \[[@B21]\]. A SLAM score \>6 was considered as active disease \[[@B22]\]. Blood samples were taken after overnight fasting and laboratory examinations were performed blinded, either on fresh blood samples or after storage in -70°C. When stored samples were used (see Table [1](#T1){ref-type="table"}), all samples were frozen and each investigation was carried out in one session.

###### 

Baseline characteristics of patients

  ------------------------------------------------------------------------------------------------------------------------------------
                                               All patients\         Patients who developed CVE\   Patients free of CVE\   *P*
                                               N = 182               N = 24                        N = 158                 
  -------------------------------------------- --------------------- ----------------------------- ----------------------- -----------
  **Traditional risk factors**                                                                                             

  Age years                                    45 (31-53)            59 (49 to 66)                 44 (30-52)              \< 0.0001

  Male gender                                  10%                   9%                            11%                     

  Smoking ever                                 51%                   70%                           46%                     0.02

  Hypertension                                 30%                   42%                           28%                     

  Systolic blood pressure (mmHg)\*             125 (115 to 140)      140 (120 to 143)              120 (110 to 140)        0.03

  Hypercholestrolemia                          41%                   54%                           39%                     

  Total cholesterol (mmol/L)                   4.9 (4.3 to 5.9)      5.7 (4.5 to 6.4)              4.9 (4.2 to 5.7)        0.05

  LDL (mmol/L)                                 2.8 (2.3 to 3.5)      3.0 (2.7 to 4.0)              2.8 (2.2 to 3.5)        

  HDL (mmol/L)                                 1.4 (1.1 to 1.7)      1.3 (1.0 to 1.9)              1.4 (1.1 to 1.7)        

  Triglycerides (mmol/L)\*                     1.3 (1.0 to 1.9)      1.5 (1.2 to 2.0)              1.2 (0.9 to 1.9)        

  ApoB/ApoA\*†                                 0.5 (0.3 to 0.6)      0.6 (0.4 to 0.8)              0.5 (0.3 to 0.6)        

  Diabetes                                     2%                    0%                            2%                      

                                                                                                                           

  **Lupus manifestations**                                                                                                 

  Disease duration                             10 (4 to 18)          18 (10 to 24)                 10 (4 to 17)            0.0005

  Malar rash                                   58%                   58%                           58%                     

  Discoid rash                                 22%                   22%                           22%                     

  Photosensitivity                             71%                   50%                           75%                     0.01

  Oral ulcers                                  29%                   37%                           27%                     

  Arthritis                                    84%                   100%                          82%                     0.02

  Pleuritis                                    38%                   65%                           34%                     0.005

  Pericarditis                                 18%                   17%                           22%                     

  Nephritis                                    30%                   37%                           29%                     

  Neurological disorder                        12%                   17%                           11%                     

  Leucopenia                                   56%                   57%                           46%                     

  Thrombocytopenia                             21%                   4%                            24%                     0.03

  Previous venous occlusion                    12%                   29%                           9%                      0.004

  SLICC \>1                                    53%                   79%                           49%                     0.006

  SLAM \>6 at baseline                         45%                   50%                           44%                     

                                                                                                                           

  **Medication**                                                                                                           

  Months on steroid treatment\*                35 (3 to 118)         54 (1 to 123)                 31 (3 to119)            

  Cyclofosfamide treatment ever                15%                   8%                            16%                     

  Azathioprine at baseline                     38%                   4%                            33%                     

  Chloroquine/Hydroxychloroquine at baseline   29%                   21%                           30%                     

  Warfarin at baseline                         9%                    13%                           8%                      

  ASA at baseline                              19%                   25%                           18%                     

  Statins at baseline                          0.6%                  0%                            0.7%                    

                                                                                                                           

  **Autoantibodies against**                                                                                               

  dsDNA                                        36%                   33%                           36%                     

  CL IgG                                       47%                   58%                           46%                     

  CL IgM                                       15%                   21%                           14%                     

  β~2~GP-1 IgG†                                36%                   54%                           34%                     0.05

  Lupus anticoagulant                          21%                   25%                           20%                     

  any PL                                       65%                   83%                           63%                     0.05

  SSA                                          43%                   25%                           46%                     

  SSB                                          24%                   13%                           25%                     

  Sm                                           11%                   8%                            12%                     

  RNP                                          11%                   14%                           11%                     

                                                                                                                           

  **Markers of systemic inflammation**                                                                                     

  hs CRP (mg/L)\*†                             1.9 (0.7 to 5.1)      4.9 (1.7 to 23.5)             1.7 (0.6 to 4.1)        0.0002

  Fibrinogen (g/L)\*†                          3.4 (2.9 to 4.5)      4.6 (3.3 to 5.3)              3.2 (2.8 to 4.3)        0.002

  α-1 antitrypsine (g/L)†                      1.5 (1.3 to 1.7)      1.8 (1.4 to 2.2)              1.5 (1.3 to 1.7         0.002

  SAA (mg/L)\*†                                5.0 (2.5 to 10.9)     9.3 (5.1 to 26.8)             4.5 (2.3 to 9.3         0.004

  IL 6 (ng/L)\*†                               3.3 (2.0 to 6.9)      5.3 (2.7 to 10.9)             3.1 (1.9 to 6.4)        0.03

  C3 (g/L)†                                    1.0 (0.8 to 1.2)      1.0 (0.9 to 1.3)              1.0 (0.8 to 1.2)        

  C3d (mg/L)†                                  11.8\                 12.9\                         11.6\                   
                                               (9.6 to 14.7)         (10.5 to 15.9)                (9.5 to 14.5)           

  C4 (g/L)†                                    0.1 (0.1 to 0.2)      0.1 (0.09 to 1.4)             0.1 (0.1 to 0.2)        

                                                                                                                           

  **Markers of endothelial activation**                                                                                    

  sVCAM-1 (ng/L)\*†                            306 (252 to 385)      373 (303 to 503)              302 (249 to 375)        0.0009

  von Willebrand factor %\*†                   117 (61 to 166)       157 (114 to 232)              112 (59 to 158)         0.001

                                                                                                                           

  **Markers of renal damage**                                                                                              

  Creatinine (μmol/L)\*                        82 (73 to 94)         87 (76 to 107)                81 (72 to 93)           0.01

  MDRD ml/min/1.73 m^2^                        68 (57 to 80)         59 (45 to 71)                 69 (58 to 81)           0.004

  Blood urea nitrogen mmol/L†                  5.7 (4.7 to 7.2)      6.5 (5.3 to 9.9)              5.6 (4.6 to 6.8)        0.01

  Pathologic urine                             23%                   25%                           22%                     

                                                                                                                           

  **Other biomarkers**                                                                                                     

  Albumin (g/L)                                45 (41 to 48)         41(37 to 45)                  45 (42 to 48)           0.002

  Homocystein (μmol/L)\*†                      12.3 (10.0 to 15.6)   12.1 (10.4 to 17.9)           12.4 (9.8 to 15.4)      
  ------------------------------------------------------------------------------------------------------------------------------------

Distributions are given as % or median (interquartile range). *P*values, not adjusted for age, ≤ 0.05 are presented. \* indicate not normally distributed variables. † indicate that analyses were done on frozen samples. Hypertension was defined as a systolic blood pressure \>140 mm Hg and/or a diastolic blood pressure \>90 mmHg and/or present treatment for hypertension. Hypercholesterolemia was defined as a total cholesterol level \>5.2 mmol/L.

β~2~GP-1 = beta~2~glykoprotein-1; any PL = positive antibody test against CL IgG or IgM, β~2~GP-1 IgG or a positive lupus anticoagulant test; ApoB/ApoA = apolipoprotein B/A. Disease manifestations were defined according to the 1982 revised American College of Rheumatology (ACR) criteria for classification of SLE \[[@B19]\]; C = Complement factor; C3d = Complement factor 3 degradation products; CL = cardiolipin; dsDNA = doublestranded DNA; HDL = high density lipoprotein; hsCRP = high sensitivity C reactive protein; IL-6 = interleukin 6; LDL = low density lipoprotein; MDRD = Estimated glomerular filtration rate using the Modification of Diet in Renal Disease (MDRD) formula \[[@B51]\]. Pathologic urine as defined by SLAM \[[@B20]\]; PL = phospholipid; RNP = r ibonucleoprotein; SAA = serum amyloid A; SLAM = a measure of disease activity \[[@B20]\]; SLICC = a measure of cumulative disease damage \[[@B21]\], Sm = Smith; SSA = Sjogrens syndrome A;

SSB = Sjogrens syndrome B; sVCAM-1 = soluble vascular cell adhesion molecule 1.

Pathologic urine as defined by SLAM \[[@B20]\].

Outcome measures of CVE
-----------------------

CVE were defined as: 1) Ischemic heart disease (IHD): myocardial infarction (MI, confirmed by electrocardiography and a rise in plasma creatine kinase, muscle and brain fraction (CK-MB) or troponin T) or angina pectoris (confirmed by exercise stress test).

2\) Ischemic cerebrovascular disease (ICVD): cerebral infarction (confirmed by computer tomography) or transitory ischemic attacks (TIA, defined as transient focal symptoms from the brain or retina with a maximum duration of 24 hours).

3\) Ischemic peripheral vascular disease (IPVD): intermittent claudication or peripheral arterial thrombosis/embolus (confirmed by angiogram or Doppler flow studies).

4\) Death due to ischemic vascular disease: death due to myocardial infarction, heart failure, sudden death, cerebral infarction, generalized atherosclerosis as stated by death certificate.

Laboratory Methods
------------------

High sensitivity C-reactive protein (CRP), α-1 antitrypsine, fibrinogen and Serum Amyloid A (SAA) were measured using BN ProSpec System (Dade Behring, Deerfield, IL, USA). C3 and C4 were analyzed using IMMAGE™ and C3d using an ARRAY™ system (both instruments are from Beckman Coulter, Brea, CA, USA). Albumin, apolipoprotein A1, apolipoprotein B and homocysteine were measured on an Architect Ci8200 analyzer (Abbott Laboratories, Abbott Park, IL, USA).

Enzyme-linked immunosorbent assays (ELISA) were used to measure Vascular cell adhesion molecule (VCAM-1, DY809, R&D Systems, Minneapolis, MN, USA), vWF (antisera from Dako (Glostrup, Denmark) calibrated against Liatest (Diagnostica Stago, Asnieres, France), intra-assay coefficient of variation were \<7%) and Interleukin 6 (IL-6, high sensitive ELISA, HS600, R&D Systems, Minneapolis, MN, USA).

Antinuclear antibodies (ANA) were analysed by immunofluorescence on sections of rat liver and HEp-2 cells (Immunoconcepts, Sacramento, CA, USA) and auto-antibodies to Sjögren\'s syndrome A and B (SSA, SSB), Smith (Sm) and Ribonucloprotein (RNP) using ANA-profile ELISA (Pharmacia Diagnostics, Uppsala, Sweden), Innolia Immunoblot (Innogenetics, N.U. Ghent, Belgium), and Auto Immunodiffusion (Immunoconcepts, Sacramento, CA, USA). Anti-double-stranded DNA (dsDNA) antibodies were determined by IFL using *Crithidia lucillae*kinetoplast assay (Immunoconcepts, Sacramento, CA, USA). Anticardiolipin antibodies (aCL) were measured by ELISA using ethanol fixed cardiolipin (Sigma-Aldrich, St Louis, MO, USA) and HRP-conjugated rabbit immunoglobulins against human IgG, respectively IgM (Dako, Glostrup, Denmark). The levels of positivity were calibrated against Harris standard (Louisville, LAPL-GM-001). Low aCL level corresponded to 10-20, medium level to 20-80 and high level to \>80 GPL/MPL Units. The cut off values for positive aCL was calculated to be at least the 95^th^percentile of healthy blood donors. Autoantibodies to β~2~-glycoprotein1 (β~2~GP1, IgG) were analysed by ELISA (Orgentec, Mainz, Germany). Positive cut-off level was used according to the manufacturer\'s descriptions. Borderline results were regarded as negative. Lupus anticoagulant (LAC) was determined using a modified Dilute Russel Viper Venom method, (Biopool, Umea, Sweden) using Bioclot LAC.

Statistics
----------

Patient characteristics were summarized for all patients and by CVE occurrence and were compared using ANOVA, Mann-Whitney U-test and X^2^test as needed. Log transformation was used for skewed continuous variables. Hazard ratios (HR) and 95% confidence intervals (95% CI) for the first CVE were calculated in uni- and multivariable-adjusted Cox regression models for baseline factors.

Variables were first sorted into functional groups (traditional risk factors, lupus manifestations etc. see Table [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). After adjusting for age, the variables within each group, which were representative and most significantly associated with future CVEs were entered into a multivariable-adjusted model. Because of a limited number of first CVEs, we restricted the number of variables in the multivariable-adjusted model to four. Calculations were done using JMP software (SAS Institute, Carey, North Carolina, USA). A *P*value \< 0.05 was considered statistically significant.

###### 

Baseline predictors of the first ever cardiovascular event, page-adjusted Cox regression models

                                               Hazard Ratio   95% Confidence interval   *P*
  -------------------------------------------- -------------- ------------------------- -----------
  **Traditional risk factors**                                                          
  Age univariate                               2.28\*         1.67 to 2.10              \< 0.0001
                                               Age adjusted                             
  Male gender                                  0.71           0.11 to 2.41              
  Smoking, ever                                2.62           1.11 to 7.03              0.03
  Hypertension                                 0.72           0.30 to 1.70              
  Systolic blood pressure                      0.78           0.52 to 1.18              
  Hypercholesterolemia                         1.37           0.61 to 3.14              
  Total cholesterol                            1.19           0.81 to 1.74              
  LDL                                          1.23           0.80 to 1.89              
  HDL                                          0.77           0.34 to 1.62              
  Triglycerides†                               1.21           0.86 to 1.69              
  ApoB/ApoA†                                   1.36           0.88 to 2.10              
  Diabetes                                     ‡              ‡                         0.02
                                                                                        
  **Manifestations of Lupus**                                                           
  Disease duration                             1.28           0.98 to 1.68              
  Malar rash                                   1.09           0.72 to 1.67              
  Discoid lupus                                0.80           0.45 to 1.26              
  Photosensitivity                             0.69           0.46 to 1.04              
  Oral ulcers                                  1.40           0.90 to 2.14              
  Arthritis                                    §              §                         0.002
  Pleuritis                                    1.60           1.02 to 2.46              0.04
  Pericarditis                                 1.35           0.77 to 2.16              
  Nephritis                                    1.31           0.85 to 1.97              
  Leukopenia                                   0.94           0.62 to 1.42              
  Thrombocytpenia                              0.37           0.09 to 0.83              0.009
  Neurologic disorder                          0.78           0.48 to 1.44              
  Previous venous occlusion                    1.88           1.16 to 2.90              0.01
  SLICC\>1                                     1.91           0.74 to 5.97              
  SLAM\>6 at baseline                          1.25           0.83 to 1.87              
                                                                                        
  **Medications**                                                                       
  Months on steroid treatment                  1.00           0.68 to 1.48              
  Cyclofosfamide treatment ever                0.60           0.01 to 2.03              
  Azathioprine at baseline                     0.51           0.03 to 2.47              
  Chloroquine/Hydroxychloroquine at baseline   1.01           0.32 to 2.67              
  Warfarin at baseline                         1.45           0.34 to 4.27              
  ASA at baseline                              1.54           0.55 to 3.70              
                                                                                        
  **Autoantibodies against**                                                            
  dsDNA                                        1.41           0.57 to 3.25              
  CL IgG                                       2.57           1.13 to 6.13              0.02
  CL IgM                                       1.35           0.45 to 3.41              
  β~2~GP1 IgG                                  2.57           1.13 to 5.99              0.02
  Lupus anticoagulant                          1.10           0.40 to 2.63              
  Any aPL                                      4.90           1.76 to 17.72             0.002
  SSA                                          0.66           0.39 to 1.03              
  SSB                                          0.57           0.27 to 1.00              0.05
  Sm                                           1.21           0.48 to 2.29              
  RNP                                          1.60           0.76 to 2.87              
                                                                                        
  **Markers of systemic inflammation**                                                  
  hs CRP†                                      1.36           0.85 to 2.18              
  Fibrinogen†                                  1.72           1.10 to 2.68              0.02
  α-1 antitrypsine                             1.49           1.01 to 2.18              
  SAA†                                         1.36           0.88 to 2.09              
  IL 6†                                        1.26           0.87 to 1.82              
  C3                                           0.92           0.63 to 1.35              
  C3d                                          1.38           0.85 to 2.22              
  C4                                           0.82           0.56 to 1.18              
                                                                                        
  **Markers of endothelial activation**                                                 
  sVCAM-1†                                     1.78           1.20 to 2.65              0.005
  von Willebrand factor†                       2.05           1.23 to 3.42              0.004
                                                                                        
  **Markers of renal involvement**                                                      
  Creatinine†                                  1.17           0.74 to 1.85              
  MDRD                                         1.07           0.57 to 2.00              
  Blood urea nitrogen                          1.15           0.75 to 1.77              
  Pathological urine                           2.4            0.8 to 6.1                
                                                                                        
  **Other biomarkers**                                                                  
  Albumin(g/l)                                 0.56           0.41 to 0.78              0.002
  Homocystein (μmol/l)†                        0.79           0.52 to 1.21              

Calculations were done using age-adjusted Cox regression. For continuous variables Hazard Ratio (HR) is given as risk per standard deviation, \*For age HR is calculated per 10 years (HR/10 years). †calculations were done on log transformed values. *P*values ≤ 0.05 are presented. ‡ Infinite coefficient, due to no AE in the diabetes group. §Infinite coefficient, due to all AE in the arthritis group, confidence interval could thus not be determined for these two variables. Hypertension was defined as a systolic blood pressure \>140 mm Hg, and/or a diastolic blood pressure \>90 mmHg and/or present treatment for hypertension. Hypercholesterolemia was defined as a total cholesterol level \>5.2 mmol/L.

β~2~GP-1 = beta2glykoprotein-1; β~2~GP-1 IgG or a positive lupus anticoagulant test;

any PL = positive antibody test against CL IgG or IgM; ApoB/ApoA = apolipoproteinB/A. Disease manifestations were defined according to the 1982 revised American College of Rheumatology (ACR) criteria for classification of SLE \[[@B19]\]; C = Complement factor; C3d = Complement factor 3 degradation products; CL = cardiolipin; dsDNA = doublestranded DNA; HDL = high density lipoprotein; hsCRP = high sensitivity C reactive protein; IL-6 = interleukin 6; LDL = low density lipoprotein;

MDRD = Estimated glomerular filtration rate using the Modification of Diet in Renal Disease (MDRD) formula \[[@B51]\]. Pathologic urine as defined by SLAM \[[@B20]\]; PL = phospholipid; RNP = ribonucleoprotein; SAA = serum amyloid A; SLAM = a measure of disease activity \[[@B20]\]; SLICC = a measure of cumulative disease damage \[[@B21]\]; Sm = Smith; SSA = Sjogrens syndrome A; SSB = Sjogrens syndrome B; sVCAM-1 = soluble vascular cell adhesion molecule 1.

Results
=======

Baseline data and clinical manifestations
-----------------------------------------

As expected, patients who developed a first CVE were older, more likely to have ever smoked, have higher total cholesterol levels and to have higher systolic blood pressure. Furthermore, they had a longer mean SLE duration, were more likely to have had previous venous occlusion, pleuritis, arthritis and leucopenia but were less likely to have photosensitivity or thrombocytopenia. Several markers of systemic inflammation, endothelial activation and renal damage, together with aPL, were elevated at baseline in patients who developed a first CVE (Table [1](#T1){ref-type="table"}).

Cardiovascular events
---------------------

Surviving patients were reinvestigated after a mean time of 8.3 ± 1.2 years. A total 132 patients were examined in person, and 34 through a structured telephone interview. Fifteen patients were deceased and their death certificates were investigated. Five autopsies had been performed and all protocols were reviewed. Medical files were reviewed for all with the exception of one patient who was unwilling to participate at follow up, thus her history of CVE could not be determined.

Twenty-four new CVEs occurred, three of which were fatal (two heart failures, one atherosclerosis according to death certificates) (Table [3](#T3){ref-type="table"}).

###### 

Age at and type of first cardiovascular event

  Type of cardiovascular event           Number of events   Median age at onset   Age range
  -------------------------------------- ------------------ --------------------- --------------
  All cardiovascular events              24                 64.4                  40.6 to 85.1
  Ischemic heart disease                 10                 60.8                  40.6 to 85.1
  Ischemic cerebrovascular disease       6                  65.7                  49.9 to 83.9
  Ischemic peripheral vascular disease   5                  55.1                  44.1 to 82.4
  Death due to cardiovascular disease    3                  64.7                  58.1 to 68.6

Ischemic heart disease = myocardial infarction or angina pectoris, ischemic cerebrovascular disease = cerebral infarction or transitory ischemic attacks, ischemic peripheral vascular disease = intermittent claudication or peripheral arterial thrombosis/embolus, death due to ischemic vascular disease = death due to myocardial infarction, heart failure, sudden death, cerebral infarction, generalized atherosclerosis as stated by death certificate.

Prospective evaluation of risk factors for CVEs
-----------------------------------------------

As expected, age was a strong predictor of the first CVE, we therefore adjusted all measurements for age. Thereafter, only smoking of the traditional risk factors remained as a predictor of CVEs. Of lupus manifestations arthritis, pleuritis, previous venous occlusion and absence of thrombocytopenia were associated with first CVEs. Among biomarkers aPL (aCL IgG, β GP1 IgG and any aPL), fibrinogen, markers of endothelial activation (sVCAM-1 and vWf), low levels of plasma albumin, and absence of SSB antibodies remained as predictors of the first CVE. All patients with a first CVE had arthritis, and none had diabetes, therefore these variables could not be further evaluated (Table [2](#T2){ref-type="table"}). In a multivariable-adjusted model age, any positive aPL, and vWf were positively associated with CVEs, while thrombocytopenia was inversely associated (Table [4](#T4){ref-type="table"}). In an alternative model we exchanged vWf for sVCAM-1. sVCAM remained in this model, together with the other variables in Table [4](#T4){ref-type="table"}, as an independent predictor of CVEs (Relative Risk for sVCAM-1 = 2.11, 95%CI (1.24 to 3.58), *P*= 0.005).

###### 

Baseline predictors of the first ever cardiovascular event, multivariable-adjusted Cox regression

                           Hazard Ratio   Confidence interval   *P*
  ------------------------ -------------- --------------------- -----------
  Age\*                    2.39           1.71 to 3.32          \< 0.0001
  Thrombocytopenia         0.35           0.08 to 0.77          0.005
  Any aPL                  4.23           1.56 to 14.83         0.003
  von Willebrand factor†   1.97           1.16 to 3.33          0.01

Calculations were done using multivariable-adjusted Cox regression. \*For age hazard ratio is calculated per 10 years (HR/10 years), for von Willebrand factor hazard ratio is given as risk per standard deviation, †calculations were done on log transformed values.

Discussion
==========

This is, to our knowledge, the first study to investigate predictors of the first ever CVE in SLE and a novel observation is that high levels of endothelial markers precede these events. We also identified SLE manifestations and can confirm \[[@B8]\] occurrence of aPLs as predictors of first CVEs. It is of note that, with the exception of age and smoking, traditional CAD risk factors did not explain CVEs in this study.

In healthy individuals high circulating levels of vWf predicted CVEs in several studies \[[@B23],[@B24]\], but in contrast to this study, significance did not remain after adjustment for other CAD risk factors \[[@B24],[@B25]\]. Myocardial infarctions are common in conditions with high levels of vWf. Plasma levels rise during acute coronary syndromes and high levels predict less favorable long time outcome in patients with established CVD, as recently reviewed by Spiel et.al \[[@B26]\]. Inflammatory cytokines can cause release of vWf from endothelial cells into the circulation where vWf has pro-thrombotic effects as it promotes aggregation of platelets \[[@B26]\]. SLE patients with subclinical atherosclerosis have increased vWf activity in the circulation \[[@B27]\] and vWf was furthermore induced by IgG from patients with SLE and thrombotic diseases \[[@B28]\] and by anti DNA antibodies in experimental studies \[[@B29]\]. The high activity of vWf in lupus \[[@B27],[@B30]\] may thus be attributable to both pro-inflammatory cytokines and to autoantibodies, and could directly contribute to the high incidence of CVE in SLE.

VCAM-1, an endothelial adhesion molecule is shed into the circulation when the endothelium is activated. In SLE, levels of sVCAM-1 are elevated and correlate with disease activity \[[@B31]\], renal manifestations \[[@B32]\] and aPL \[[@B33]\]. We have recently demonstrated that after adjustment for nephritis, high levels of sVCAM-1 discriminated SLE patients with manifest CVD from SLE patients free of CVD and population controls \[[@B34]\]. The present study extends these findings as we can report that high levels of sVCAM-1 predict future CVE, independently of aPLs. VCAM-1 has also been reported to predict poor long-term outcome in other patient groups at risk of CVD, that is, in hemodialysis patients \[[@B35]\], in patients with diabetic nephropathy \[[@B36]\] and in patients with manifest CAD \[[@B37]\]. Both vWf and VCAM-1 are markers of endothelial activation. Other studies have reported impaired endothelial function as measured by flow mediated dilatation \[[@B38]\] and that increased numbers of circulating apoptotic endothelial cells are present in SLE patients \[[@B39]\]. Taken together many studies report that endothelial perturbation occurs in SLE, and our results suggest that it precedes the first CVE.

In the general population, systemic inflammatory activity, often measured by CRP, is a well-documented risk factor for CVD. A similar role for fibrinogen, SAA and IL-6, has also been reported \[[@B40]\]. At baseline elevation of several inflammatory markers were more prevalent among patients who experienced their first CVE during follow-up, but after adjustment for age, only fibrinogen remained as a significant predictor. Fibrinogen is an important clotting protein, and high levels have been reported in SLE patients with a history of thrombotic disease \[[@B41]\]. CRP has previously been identified as a risk factor for arterial disease in SLE, but we were not able to replicate those results \[[@B8]\].

Patients with a positive test for any aPL had a higher risk of CVEs confirming previous findings by Toloza et.al \[[@B8]\]. Positive IgG titers of aCL, or β~2~GP1, were predictive of CVE. However, IgM aCL and LAC were not. Any positive aPL were more common in this study (65%) than reported in most \[[@B7],[@B33],[@B42]\] lupus cohorts possibly indicating a low cut-off level at our laboratory in the mid 90\'s when baseline data were collected. It is therefore interesting to note that any aPL were only predictive of CVEs when we included the cut-off for positive tests. With a cut-off at medium titer, more in accordance with the definition of the anti-phospholipid syndrome (APS) \[[@B43]\], baseline aPLs were no longer significantly associated with future CVE (data not shown). This may be explained by limited power, as few patients had medium/high titer aPL, and by the fact that these patients were more often on anti-coagulation treatment. Nevertheless, our results suggest that also low titer aPL adds to the risk of CVEs in SLE patients.

We noted that subsets of patients with different lupus manifestations seemed to have a differentiated risk of CVE. Arthritis and pleuritis are SLE manifestations, often associated with a more pronounced acute phase response \[[@B15],[@B44]\], and patients with these symptoms had a higher risk of developing a first CVE, as also reported by Mok et al \[[@B16]\]. Patients with a previous episode of venous occlusion, a major manifestation of APS \[[@B43]\], were more likely to present with a first CVE. They were also more likely to have any positive aPL (Odds Ratio = 12.5, 95% CI (1.6 to 95.7), *P*= 0.0005). The observation that patients with previous thrombocytopenia, also associated with APS \[[@B43]\], were at lower risk of CVEs is new. Previous studies have demonstrated that thrombocytopenia is often associated with auto antibodies to platelet glycoproteins, but these antibodies have not been linked to thrombosis \[[@B45]\]. Hypothetically a low platelet count could confer a protective anti-coagulant effect, but this would need to be tested in larger samples. Another novel observation is that patients with photosensitivity and SSA/SSB antibodies, which often occur together, may be at lower CVD risk as compared to other SLE patients. Taken together, this study suggests that subgroups of SLE patients are not affected with the same high risk of CVEs. Larger cohort studies are needed to confirm these observations.

Besides age, smoking was the only traditional CVD risk factor which predicted CVEs in this study, this is in line with the results of Toloza et al \[[@B8]\] Lipid derangements including hypercholesterolemia, elevated ApoB/ApoA ratio, low HDL and hypertriglyceridemia, did not remain statistically significant after adjustment for age. Earlier studies are inconsistent with regard to the impact of blood lipids on CVD in SLE. Some have reported an association between manifest CVD and hypercholesterolemia \[[@B46],[@B47]\], hypertriglyceridemia \[[@B48],[@B49]\] or low HDL \[[@B4],[@B16]\] whereas this study and the prospective study from the LUMINA cohort did not find an association \[[@B8]\].

After adjusting for age, a lower estimated glomerular filtration rate at baseline was not predictive of presenting with a first CVE in this study. Hypoalbuminemia, positively associated both with markers of systemic inflammation and with loss of renal function (data not shown), was however a strong predictor. It was not entered into the multivariable-adjusted model because we regarded it as a proxy for both systemic inflammation and for renal disease. Its significance may however be useful since albumin measurements are inexpensive and commonly used in clinical practice.

The relatively small number of patients and events in the present study are limitations, which call for some caution, in particular with regard to subgroup analysis. It may also explain the lack of association with traditional CAD risk factors. The great majority of our patients were Caucasians of European origin, thus confirmation in other ethnic groups is needed before generalizing our results to SLE cohorts from other parts of the world. The detailed baseline information and the relatively long and almost complete follow-up including all deceased patients are strengths of the study. The fact that we only included the first ever CVE is a merit, but also a reason for the low number of events. Several patients eventually experienced additional events. Of note 9/24 patients (38%) who experienced a first CVE were dead when we closed the study in 2007. This figure further highlights the importance of conducting longitudinal prospective studies.

Due to the design of this study and the clinical definitions used for CVEs it was not possible to compare the incidence of CVEs in these lupus patients with the general population. However, other studies have shown that patients with SLE have a marked increased risk of CVD as compared to the general population \[[@B2],[@B15],[@B50]\].

Conclusions
===========

In conclusion this prospective study is the first to investigate lupus associated and CAD risk factors for the first ever CVE in patients with SLE. In addition to age, positive aPL, biomarkers indicating increased endothelial cell activity/damage, and absence of thrombocytopenia were independent predictors of CVEs. Our results indicate that activation of the endothelium and the coagulation system are important features in SLE related CVD. Furthermore, the risk of CVEs seems to differ between subgroups of SLE patients. How these findings influence and interact with the presence of premature atherosclerosis, not measured in this study, remains to be determined.
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